Back
Proto Labs 10K Form
Buy
70
PRLB
Proto Labs
Last Price:
38.03
Seasonality Move:
11.84%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-03 | 10Q | PRLB/Proto Labs Quarterly |
| 2024-02-16 | 10K | PRLB/Proto Labs Annual |
| 2023-11-03 | 10Q | PRLB/Proto Labs Quarterly |
| 2023-08-04 | 10Q | PRLB/Proto Labs Quarterly |
| 2023-05-05 | 10Q | PRLB/Proto Labs Quarterly |
| 2023-02-21 | 10K | PRLB/Proto Labs Annual |
Receive PRLB News And Ratings
See the #1 stock for the next 7 days that we like better than PRLB
PRLB Financial Statistics
Sales & Book Value
| Annual Sales: | $503.88M |
|---|---|
| Cash Flow: | $10.25M |
| Price / Cash Flow: | 19.96 |
| Annual Sales: | $27.25 |
| Price / Book: | 1.4 |
Profitability
| EPS (TTM): | 0.96000 |
|---|---|
| Net Income (TTM): | $24.75M |
| Gross Margin: | $221.99M |
| Return on Equity: | 3.6% |
| Return on Assets: | 3.21% |
Proto Labs Earnings Forecast
Key Proto Labs Financial Ratios
- The Gross Profit Margin over the past 15 years for PRLB is 44.06%.
- The Selling, General & Administrative Expenses for PRLB have been equal to 30.46% of Gross Profit Margin.
- The Research & Development expenses have been 7.97% of Revenue.
- The Interest Expense is 0.00% of Operating Income.
- The Net Earning history of PRLB is 3.42% of Total Revenues.
- Per Share Earnings over the last 15 years have been positive in 9 years.
Proto Labs Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NYSE |
|---|---|
| Industry: | Machinery |
| Sector: | Industrials |
| Current Symbol: | PRLB |
| CUSIP: | 743713 |
| Website: | protolabs.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 4.08 |
| Quick Ratio: | 3.64 |
Price-to-Earnings
| Trailing P/E Ratio: | 57.62 |
|---|---|
| Forward P/E Ratio: | 25.91 |
PRLB Technical Analysis vs Fundamental Analysis
Buy
70
Proto Labs (PRLB)
is a Buy
Is Proto Labs a Buy or a Sell?
-
Proto Labs stock is rated a Buy
The current Proto Labs [PRLB] share price is $38.00. The Score for PRLB is 70, which is 40% above its historic median score of 50, and infers lower risk than normal.